...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054)
【24h】

Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054)

机译:使用特定的内皮素A受体拮抗剂Zibotentan(ZD4054)治疗的无痛或轻度症状的转移性激素抵抗性前列腺癌患者的健康相关生活质量

获取原文
获取原文并翻译 | 示例

摘要

Purpose Zibotentan (ZD4054) is a specific endothelin A receptor antagonist in clinical development for the treatment of hormone-resistant prostate cancer (HRPC). In a Phase II trial in patients with pain-free or mildly symptomatic metastatic HRPC, zibotentan was well tolerated with a promising signal for prolonged overall survival compared with placebo. As part of this trial, the impact of zibotentan compared with placebo on health-related quality of life (HRQoL) was assessed.
机译:目的Zibotentan(ZD4054)是在临床开发中用于治疗激素抵抗性前列腺癌(HRPC)的特异性内皮素A受体拮抗剂。在一项针对无痛或轻度有症状转移性HRPC的患者的II期试验中,与安慰剂相比,zibotentan具有良好的耐受性,并具有可延长总体生存期的有希望的信号。作为该试验的一部分,评估了与安慰剂相比,zibotentan对健康相关生活质量(HRQoL)的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号